Canakinumab use in FMF and Still's disease patients across real-world care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study characterizes treatment patterns, long-term clinical outcomes, and patient demographics for individuals with FMF or Still's disease (including SJIA and AOSD) who received canakinumab for six months or longer. Data are drawn from real-world clinical use up to October 2021, with a minimum follow-up of three years post-treatment initiation. The analysis focuses on how canakinumab is used in routine practice and its associated outcomes and quality of life. No interventional procedures are mandated; the study relies on existing medical records to describe patterns and outcomes. The sponsor is Novartis, based in Basel, with no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

Exclusion criteria:

• Patients Aged \<2 Years (24 Months) at Index Date.

Where it's running

• Novartis
  Basel, Switzerland Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Allogeneic HCT for Refractory sJIA in Children and Young Adults

  This study tests whether donor blood-forming cell transplantation can help children and young adults with difficult-to-treat systemic JIA, including those with lung involvement.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07845942

• Canakinumab use in Schnitzler’s syndrome in real-world patients

  This study tests how well and how safely canakinumab works for people diagnosed with Schnitzler’s syndrome who are taking it in routine clinical care.

  Recruiting at 5 sites Novartis · Kobe, Hyōgo and 4 other locations · NCT07598422

• Mediterranean diet with or without aerobic exercise for women with familial Mediterranean fever and fatty liver

  This trial will test whether adding regular aerobic exercise to a Mediterranean diet helps women with familial Mediterranean fever who have non-alcoholic fatty liver disease.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07130318

• Whole-body vibration plus vitamin D for adolescent girls with familial Mediterranean fever

  This project will try adding regular whole-body vibration sessions to vitamin D and usual colchicine for girls aged 13–17 with familial Mediterranean fever to see if it improves fitness, muscle strength, and bone mass.

  Recruiting Cairo University · Giza, Dokki · NCT07130305

• Inspiratory muscle training for adolescents with Familial Mediterranean Fever

  This trial will try a daily inspiratory muscle training program to see if it improves breathing strength, exercise tolerance, and fatigue in teenagers (ages 13–17) with Familial Mediterranean Fever who are taking colchicine.

  Recruiting Cairo University · Giza, Dokki · NCT07129538

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.